Surprisingly, healthy cells appear to be resilient to genetic ablation of the circadian clock, as Bmal1 disruption does not produce any gross hematopoietic deficits, thus revealing Bmal1 as an attractive anti-leukemia target [119]. The gene discussed is BMAL1; the disease is leukemia.